查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1456941

生育力測試市場－2024年至2029年預測

Fertility Test Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

不孕症檢測市場預計將從2022年的531,831,000美元增加到2029年的775,732,000美元，複合年成長率為5.54%。

不孕症檢測市場受到多種因素的影響，包括人們對不孕症問題的認知提高和檢測技術的進步。持續的技術改進正在提高這些測試的準確性、易用性和可訪問性，從而提高普及率。此外，人們越來越重視預防性醫療保健，增加了對不孕症檢測的需求，將其視為管理整體生殖健康和及早發現潛在問題的主動手段。

市場區隔包括排卵預測套件、生育力監測儀、男性不孕測試和其他選擇。排卵預測套件迎合尋求自然受孕的女性，並提供多種選擇，包括尿液檢查、唾液測試和數位監測器。生育力監測儀提供先進的功能，如周期追蹤和個人化見解。

男性不孕症檢測套組可用於家庭使用和臨床使用，並評估活力、濃度和型態等因素。其他選擇包括荷爾蒙檢測套組、卵巢儲備檢測套組和基因檢測套組。

從市場區隔來看，市場分為女性不孕檢測與男性不孕檢測。女性不孕症檢測包括針對月經和荷爾蒙水平不同方面的各種檢測，反映了女性不孕症的盛行率較高。相反，男性不孕測試顯示人們對預防醫學的興趣日益濃厚，從而導致了方便用戶使用的家庭檢測套組的開發。

根據最終用戶細分，市場分為居家照護機構和醫院/生育診所。排卵預測套件和基本精液分析套件等非處方箋(OTC) 測試主要用於居家醫療環境。相較之下，醫院和生育診所提供全面的生育測試，包括處方箋荷爾蒙評估和專業診斷評估。

儘管面臨人口結構變化和醫療保健環境等挑戰，但市場格局仍有望顯著成長。透過解決這些趨勢和障礙，不孕症檢測使個人和夫婦能夠就其生殖健康和計劃生育目標做出明智的決定。

市場促進因素：

  • 傳播人們對不孕症的認知的努力正在推動市場的成長。

由於不孕症旅遊和首次懷孕的增加，不孕症檢測市場預計將持續成長。此外，關於不孕症意識和早期檢測的有利舉措和宣傳活動，加上女性中 PCOD（卵巢卵巢病）患病率的增加，進一步支持了市場擴張。

用於醫療諮詢的遠距遠端醫療服務的日益普及也是不孕症檢測市場的主要驅動力。遠端醫療為個人提供了一個方便易用的平台，可以遠距接受不孕症檢查並諮詢專家，促進早期療育和個人化指導。

  • 首次生育年齡增加的趨勢

越來越多的女性出於各種原因推遲撫養孩子，包括追求高等教育、發展職業生涯和獲得財務穩定。與低度開發國家，此一趨勢在已開發國家尤為明顯，首次當媽媽的平均年齡在美國為27歲，在英國為29歲，在烏干達為19.4歲，被認為是首次當媽媽的平均年齡。根據中央情報局的資料，開發中國家正在變得越來越貴。

隨著女性推遲組建家庭，不孕症檢測對於發現可能影響懷孕和嬰兒健康的問題變得越來越重要。早期早期療育和介入可以改善妊娠結局，降低與高風險妊娠相關的風險，並有助於降低嬰幼兒死亡率。

不孕症檢測 ING 在識別可能影響懷孕和嬰幼兒健康的潛在問題方面發揮著重要作用。及時介入和治療這些問題可以改善妊娠結局，降低與高風險妊娠相關的風險，並最終有助於降低嬰兒死亡率 (IMR)。例如，2020年的IMR為29，2021年下降至28。

市場限制因素：

  • 成本限制

檢測可能是一項財務挑戰，因為它通常包括不孕不育檢測、專家諮詢和必要的後續調查的費用。這項費用可能會阻礙夫妻接受檢查，尤其是對於保險不涵蓋生育相關服務的夫婦。

雖然一些保險計劃部分或全部承保不孕不育檢查，但許多保險計劃不包括此類承保或對有資格報銷的檢查類型施加限制。可能存在這種情況。缺乏財政支持是人們尋求不孕症檢查的主要障礙。

根據購買型態，不孕症檢測市場分為處方箋和非處方箋類。

依購買型態細分不孕檢測市場，分為處方箋類和非處方箋類。已被診斷出患有不孕症或具有複雜醫學背景的人可以在醫療專業人員的指導和解釋下處方箋不孕症檢測。

相反，非處方箋(OTC) 不孕症測試適合有不孕症健康問題但未診斷出問題的個人，並且與處方箋測試相比，提供了更經濟的選擇。

北美預計將佔據不孕不育檢測市場的巨大佔有率

北美地區，尤其是美國，不孕率相對較高，受延遲生育、環境因素和生活方式選擇等因素影響。這種高盛行率強調了早期診斷和及時介入的重要性，推動了對不孕症檢測解決方案的需求增加。

在北美，男性和女性都越來越意識到自己的生育測試選擇和好處。教育宣傳活動、媒體報導和不孕症相關問題的公開討論正在促進這種認知的提高。因此，對於尋求積極主動的方法來解決不孕問題的個人來說，對不孕症檢測服務的需求不斷成長。

公司產品

  • Geratherm Medical AG - Geratherm Medical AG 是不孕不育檢測解決方案的先驅供應商之一，其主要產品「Basal」和「Early Detect」提供有關生育和早期檢測的資訊。產品「Geratherm Early Detect」可在幾分鐘內提供結果，並支持早期檢測現有懷孕。
  • Fairhaven Health - Fairhaven Health 提供由醫生設計的懷孕、不孕和哺乳產品，包括排卵預測器。
  • Mankind Pharma Ltd - Mankind Pharma Ltd 的不孕症和懷孕測試解決方案易於使用，範圍涵蓋從懷孕前到懷孕後。 PrgaNews品牌的產品提供排卵和懷孕（之前和之後）測試解決方案，包括排卵計算器和懷孕預產期計算器。

目錄

第1章 簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現
  • 分析師觀點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章不孕症檢測市場：依產品

  • 介紹
  • 排卵產品套件
    • 市場趨勢和機遇
    • 成長前景
  • 生育力監測儀
    • 市場趨勢和機遇
    • 成長前景
  • 男性生育能力檢測套組
    • 市場趨勢和機遇
    • 成長前景
  • 其他
    • 市場趨勢和機遇
    • 成長前景

第6章不孕症檢測市場：依應用分類

  • 介紹
  • 女性用生育力測試
    • 市場趨勢和機遇
    • 成長前景
  • 男性生育能力測試
    • 市場趨勢和機遇
    • 成長前景

第7章 生育力測試市場：按購買方式

  • 介紹
  • 基於處方箋
    • 市場趨勢和機遇
    • 成長前景
  • 非處方箋依據
    • 市場趨勢和機遇
    • 成長前景

第8章不孕症檢測市場：依最終用戶分類

  • 介紹
  • 居家照護環境
    • 市場趨勢和機遇
    • 成長前景
  • 醫院和生育診所
    • 市場趨勢和機遇
    • 成長前景

第9章不孕不育檢測市場：依地區

  • 介紹
  • 北美洲
    • 依產品
    • 按用途
    • 按購買方式
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 依產品
    • 按用途
    • 按購買方式
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 依產品
    • 按用途
    • 按購買方式
    • 按最終用戶
    • 按國家/地區
  • 中東/非洲
    • 依產品
    • 按用途
    • 按購買方式
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 依產品
    • 按用途
    • 按購買方式
    • 按最終用戶
    • 按國家/地區

第10章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第11章 公司簡介

  • Church & Dwight Co., Inc.
  • Geratherm Medical AG
  • Fertility Focus
  • Fairhaven Health LLC
  • bioZhena Corporation
  • Hilin Life Products, Inc.
  • UEBE Medical GmbH
  • AdvaCare Pharma
  • Mankind Pharma Ltd.
  • Modern Fertility
簡介目錄
Product Code: KSI061611911

The fertility test market is projected to rise at a compound annual growth rate (CAGR) of 5.54% to reach a market valuation of US$775.732 million by 2029, from US$531.831 million in 2022.

The fertility test market is subject to various influences, including heightened awareness of fertility issues and advancements in testing technology. Ongoing technological enhancements are improving the accuracy, ease of use, and accessibility of these tests, driving their adoption rates. Additionally, a growing emphasis on preventive healthcare is fueling demand for fertility testing as a proactive means of managing overall reproductive health and detecting potential issues early on.

In terms of product segmentation, the fertility test market encompasses ovulation product kits, fertility monitors, men's fertility testing kits, and other options. Ovulation predictor kits cater to women seeking natural conception, offering a range of choices such as urine tests, saliva tests, and digital monitors. Fertility monitors provide advanced features like cycle tracking and personalized insights.

Male fertility testing kits, available for home and clinical use, assess factors like motility, concentration, and morphology. Other options include hormone testing kits, ovarian reserve tests, and genetic testing kits.

In terms of application segmentation, the market is divided into female fertility testing and male fertility testing. Female fertility testing comprises various tests tailored to different aspects of the menstrual cycle and hormonal levels, reflecting the higher prevalence of female infertility concerns. Conversely, male fertility testing demonstrates an increasing focus on preventive healthcare, leading to the development of user-friendly home-based testing kits.

End-user segmentation categorizes the market into homecare settings and hospitals/fertility clinics. Homecare settings primarily feature non-prescription (OTC) tests such as ovulation predictor kits and basic semen analysis kits. In contrast, hospitals and fertility clinics offer a comprehensive range of fertility tests, including prescription-based hormonal assessments and specialized diagnostic evaluations.

Despite challenges like shifting demographics and healthcare landscapes, the fertility test market is poised for significant growth. By addressing these trends and obstacles, fertility testing empowers individuals and couples to make informed decisions about their reproductive health and family planning goals.

Market Drivers:

  • Initiatives to spread infertility awareness have bolstered the market growth.

The fertility test market is anticipated to grow at a constant rate, which is attributable to the growing fertility tourism and first-time pregnancies. In addition, favorable initiatives and campaigns regarding infertility awareness and early detection, coupled with the growing prevalence of PCOD (Polycystic Ovary Disease) among females, have further bolstered the market expansion.

The rising popularity of telehealth services for healthcare consultations is also significantly driving the fertility test market. Telehealth provides a convenient and accessible platform for individuals to undergo remote fertility testing and consult with specialists, facilitating early intervention and personalized guidance.

  • Trend towards a rising age of first-time mothers

Women are increasingly postponing parenthood for a variety of reasons, including pursuing higher education, advancing their careers, or attaining financial stability. This trend is particularly prominent in developed nations compared to underdeveloped ones, with the average age of first-time mothers being higher in countries such as the US (27 years), the UK (29 years), and Uganda (19.4 years), which is considered a developing country according to CIA data.

As women delay starting families, fertility testing becomes increasingly crucial in identifying potential issues that could impact pregnancy and infant health. Early detection and intervention can lead to improved pregnancy outcomes, reduce the risks associated with high-risk pregnancies, and contribute to a decline in the infant mortality rate.

Fertility testing plays a critical role in identifying potential issues that may affect both pregnancy and infant health. Timely intervention and treatment for these concerns can enhance pregnancy outcomes, mitigate risks associated with high-risk pregnancies, and ultimately contribute to reducing the infant mortality rate (IMR). For example, while the IMR was 29 in 2020, it decreased to 28 by 2021.

Market Restraint:

  • Cost-related restraints

Fertility testing procedures can pose a financial challenge, as they often include costs associated with the tests, consultations with specialists, and any necessary follow-up investigations. This expense can dissuade certain couples from pursuing testing, particularly those without insurance coverage for fertility-related services.

Although some insurance plans provide partial or complete coverage for fertility testing, many plans do not include such coverage or may impose restrictions on the types of tests eligible for reimbursement. The absence of financial assistance can be a notable obstacle for individuals seeking fertility testing.

The fertility test market is segmented by mode of purchase into prescription-based and non-prescription-based categories.

The segmentation of the fertility test market by mode of purchase divides it into prescription-based and non-prescription-based categories. Prescription-based Fertility Tests cater to individuals facing diagnosed fertility issues or possessing complex medical backgrounds, with the involvement of medical professionals offering guidance and interpretation.

Conversely, non-prescription (OTC) fertility tests are suitable for individuals with fertility health concerns but without diagnosed problems, offering a more economical option compared to prescription-based tests.

North America is anticipated to hold a significant share of the fertility test market

In North America, notably in the United States, infertility rates are relatively high, influenced by factors such as delayed childbearing, environmental factors, and lifestyle choices. This heightened prevalence underscores the importance of early diagnosis and timely intervention, driving the increasing demand for fertility testing solutions.

Both men and women in North America are becoming increasingly aware of the available fertility testing options and their associated benefits. This growing awareness is fueled by educational campaigns, media coverage, and open discussions about fertility-related issues. Consequently, there is a rising demand for fertility testing services as individuals seek proactive approaches to addressing fertility concerns.

Company Products:

  • Geratherm Medical AG - Geratherm Medical AG is one of the pioneering providers of fertility testing solutions whose major offerings, namely "Basal" & "Early Detect", assist in providing information about possible pregnancies and early detection. Product: "Geratherm Early Detect" provides results within a few minutes and assists in detecting existing pregnancies at an early stage.
  • Fairhaven Health - Fairhaven Health offers doctor-designed pregnancy, fertility & nursing products inclusive of ovulation predictors. Product: "BFP Early Ovulation Test Strips" are eco-friendly, and affordable and predict ovulation by detecting LH surge.
  • Mankind Pharma Ltd - Mankind Pharma Ltd's fertility and pregnancy testing solutions are easy to use and range from pre-pregnancy to post-pregnancy offerings. Product: The PrgaNews brand provides ovulation and pregnancy (pre- & post-) testing solutions, including an ovulation calculator and a pregnancy due date calculator.

Market Segmentation:

By Product

  • Ovulation Product Kits
  • Fertility Monitors
  • Men's Fertility Testing Kits
  • Others

By Application

  • Female Fertility Testing
  • Male Fertility Testing

By Mode of Purchase

  • Prescription based
  • Non-prescription based

By End-User

  • Homecare setting
  • Hospitals and Fertility Clinics

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Australia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits to the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. FERTILITY TEST MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. Ovulation Product Kits
    • 5.2.1. Market Trends and Opportunities
    • 5.2.2. Growth Prospects
  • 5.3. Fertility Monitors
    • 5.3.1. Market Trends and Opportunities
    • 5.3.2. Growth Prospects
  • 5.4. Men's Fertility Testing Kits
    • 5.4.1. Market Trends and Opportunities
    • 5.4.2. Growth Prospects
  • 5.5. Others
    • 5.5.1. Market Trends and Opportunities
    • 5.5.2. Growth Prospects

6. FERTILITY TEST MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Female Fertility Testing
    • 6.2.1. Market Trends and Opportunities
    • 6.2.2. Growth Prospects
  • 6.3. Male Fertility Testing
    • 6.3.1. Market Trends and Opportunities
    • 6.3.2. Growth Prospects

7. FERTILITY TEST MARKET BY MODE OF PURCHASE

  • 7.1. Introduction
  • 7.2. Prescription based
    • 7.2.1. Market Trends and Opportunities
    • 7.2.2. Growth Prospects
  • 7.3. Non-prescription based
    • 7.3.1. Market Trends and Opportunities
    • 7.3.2. Growth Prospects

8. FERTILITY TEST MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Homecare setting
    • 8.2.1. Market Trends and Opportunities
    • 8.2.2. Growth Prospects
  • 8.3. Hospitals and Fertility Clinics
    • 8.3.1. Market Trends and Opportunities
    • 8.3.2. Growth Prospects

9. FERTILITY TEST MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Mode Of Purchase
    • 9.2.4. By End-user
    • 9.2.5. By Country
      • 9.2.5.1. United States
        • 9.2.5.1.1. Market Trends and Opportunities
        • 9.2.5.1.2. Growth Prospects
      • 9.2.5.2. Canada
        • 9.2.5.2.1. Market Trends and Opportunities
        • 9.2.5.2.2. Growth Prospects
      • 9.2.5.3. Mexico
        • 9.2.5.3.1. Market Trends and Opportunities
        • 9.2.5.3.2. Growth Prospects
  • 9.3. South America
    • 9.3.1. By Product
    • 9.3.2. By Application
    • 9.3.3. By Mode Of Purchase
    • 9.3.4. By End-user
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
        • 9.3.5.1.1. Market Trends and Opportunities
        • 9.3.5.1.2. Growth Prospects
      • 9.3.5.2. Argentina
        • 9.3.5.2.1. Market Trends and Opportunities
        • 9.3.5.2.2. Growth Prospects
      • 9.3.5.3. Others
        • 9.3.5.3.1. Market Trends and Opportunities
        • 9.3.5.3.2. Growth Prospects
  • 9.4. Europe
    • 9.4.1. By Product
    • 9.4.2. By Application
    • 9.4.3. By Mode Of Purchase
    • 9.4.4. By End-user
    • 9.4.5. By Country
      • 9.4.5.1. Germany
        • 9.4.5.1.1. Market Trends and Opportunities
        • 9.4.5.1.2. Growth Prospects
      • 9.4.5.2. France
        • 9.4.5.2.1. Market Trends and Opportunities
        • 9.4.5.2.2. Growth Prospects
      • 9.4.5.3. UK
        • 9.4.5.3.1. Market Trends and Opportunities
        • 9.4.5.3.2. Growth Prospects
      • 9.4.5.4. Others
        • 9.4.5.4.1. Market Trends and Opportunities
        • 9.4.5.4.2. Growth Prospects
  • 9.5. Middle East and Africa
    • 9.5.1. By Product
    • 9.5.2. By Application
    • 9.5.3. By Mode Of Purchase
    • 9.5.4. By End-user
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
        • 9.5.5.1.1. Market Trends and Opportunities
        • 9.5.5.1.2. Growth Prospects
      • 9.5.5.2. UAE
        • 9.5.5.2.1. Market Trends and Opportunities
        • 9.5.5.2.2. Growth Prospects
      • 9.5.5.3. Israel
        • 9.5.5.3.1. Market Trends and Opportunities
        • 9.5.5.3.2. Growth Prospects
      • 9.5.5.4. South Africa
        • 9.5.5.4.1. Market Trends and Opportunities
        • 9.5.5.4.2. Growth Prospects
      • 9.5.5.5. Others
        • 9.5.5.5.1. Market Trends and Opportunities
        • 9.5.5.5.2. Growth Prospects
  • 9.6. Asia Pacific
    • 9.6.1. By Product
    • 9.6.2. By Application
    • 9.6.3. By Mode Of Purchase
    • 9.6.4. By End-user
    • 9.6.5. By Country
      • 9.6.5.1. China
        • 9.6.5.1.1. Market Trends and Opportunities
        • 9.6.5.1.2. Growth Prospects
      • 9.6.5.2. Japan
        • 9.6.5.2.1. Market Trends and Opportunities
        • 9.6.5.2.2. Growth Prospects
      • 9.6.5.3. India
        • 9.6.5.3.1. Market Trends and Opportunities
        • 9.6.5.3.2. Growth Prospects
      • 9.6.5.4. South Korea
        • 9.6.5.4.1. Market Trends and Opportunities
        • 9.6.5.4.2. Growth Prospects
      • 9.6.5.5. Taiwan
        • 9.6.5.5.1. Market Trends and Opportunities
        • 9.6.5.5.2. Growth Prospects
      • 9.6.5.6. Australia
        • 9.6.5.6.1. Market Trends and Opportunities
        • 9.6.5.6.2. Growth Prospects
      • 9.6.5.7. Others
        • 9.6.5.7.1. Market Trends and Opportunities
        • 9.6.5.7.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisition, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Church & Dwight Co., Inc.
  • 11.2. Geratherm Medical AG
  • 11.3. Fertility Focus
  • 11.4. Fairhaven Health LLC
  • 11.5. bioZhena Corporation
  • 11.6. Hilin Life Products, Inc.
  • 11.7. UEBE Medical GmbH
  • 11.8. AdvaCare Pharma
  • 11.9. Mankind Pharma Ltd.
  • 11.10. Modern Fertility